Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabio Fischetti

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
Autoimmunity|August 23, 2006
Cross-talk between the complement system and endothelial cells in physiologic conditions and in vascular diseasesFabio Fischetti, Francesco Tedesco
BMC Musculoskeletal Disorders|May 16, 2018
Hypertrophic osteoarthropathy mimicking a reactive arthritis: a case report and review of the literatureFrancesco Bozzao, Stella Bernardi, Franca Dore, et al.
Chemical Immunology and Allergy|September 1, 2005
The complement system at the fetomaternal interfaceRoberta Bulla, Fleur Bossi, Fabio Fischetti, et al.
Arthritis and Rheumatism|March 30, 2007
Selective therapeutic control of C5a and the terminal complement complex by anti-C5 single-chain Fv in an experimental model of antigen-induced arthritis in ratsFabio Fischetti, Paolo Durigutto, Paolo Macor, et al.
Blood|March 17, 2007
Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivoGiorgio Zauli, Federica Corallini, Fleur Bossi, et al.
Blood|January 5, 2002
Cytolytically inactive terminal complement complex causes transendothelial migration of polymorphonuclear leukocytes in vitro and in vivoAldo Dobrina, Mario Pausa, Fabio Fischetti, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 24, 2004
Platelet-activating factor and kinin-dependent vascular leakage as a novel functional activity of the soluble terminal complement complexFleur Bossi, Fabio Fischetti, Valentina Pellis, et al.
European Journal of Immunology|October 2, 2002
The cleavage site of C5 from man and animals as a common target for neutralizing human monoclonal antibodies: in vitro and in vivo studiesRoberto Marzari, Daniele Sblattero, Paolo Macor, et al.
Plos One|March 19, 2013
Prevention of arthritis by locally synthesized recombinant antibody neutralizing complement component C5Paolo Durigutto, Paolo Macor, Federica Ziller, et al.
Atherosclerosis|December 3, 2015
Angiotensin 1-7 significantly reduces diabetes-induced leukocyte recruitment both in vivo and in vitroFleur Bossi, Stella Bernardi, Daniele De Nardo, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Autoimmunity|August 23, 2006
Cross-talk between the complement system and endothelial cells in physiologic conditions and in vascular diseasesFabio Fischetti, Francesco Tedesco
BMC Musculoskeletal Disorders|May 16, 2018
Hypertrophic osteoarthropathy mimicking a reactive arthritis: a case report and review of the literatureFrancesco Bozzao, Stella Bernardi, Franca Dore, et al.
Chemical Immunology and Allergy|September 1, 2005
The complement system at the fetomaternal interfaceRoberta Bulla, Fleur Bossi, Fabio Fischetti, et al.
Arthritis and Rheumatism|March 30, 2007
Selective therapeutic control of C5a and the terminal complement complex by anti-C5 single-chain Fv in an experimental model of antigen-induced arthritis in ratsFabio Fischetti, Paolo Durigutto, Paolo Macor, et al.
Blood|March 17, 2007
Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivoGiorgio Zauli, Federica Corallini, Fleur Bossi, et al.
Blood|January 5, 2002
Cytolytically inactive terminal complement complex causes transendothelial migration of polymorphonuclear leukocytes in vitro and in vivoAldo Dobrina, Mario Pausa, Fabio Fischetti, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 24, 2004
Platelet-activating factor and kinin-dependent vascular leakage as a novel functional activity of the soluble terminal complement complexFleur Bossi, Fabio Fischetti, Valentina Pellis, et al.
European Journal of Immunology|October 2, 2002
The cleavage site of C5 from man and animals as a common target for neutralizing human monoclonal antibodies: in vitro and in vivo studiesRoberto Marzari, Daniele Sblattero, Paolo Macor, et al.
Plos One|March 19, 2013
Prevention of arthritis by locally synthesized recombinant antibody neutralizing complement component C5Paolo Durigutto, Paolo Macor, Federica Ziller, et al.
Atherosclerosis|December 3, 2015
Angiotensin 1-7 significantly reduces diabetes-induced leukocyte recruitment both in vivo and in vitroFleur Bossi, Stella Bernardi, Daniele De Nardo, et al.
Pageof 3